If Haemonetics was on your watchlist instead of in your portfolio, the recent move likely feels expensive. For Haemonetics shareholders, the return from the start of the year was 59.3%, including dividends. That outcome arrived after a year when analysts were split on whether plasma growth, recurring software revenue and hospital technologies could really widen margins. The puzzle now is simple: which early assumption about Haemonetics’ recurring plasma and software footprint would have helped you recognise that upside before it showed up?
On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.
This theme extends beyond Haemonetics. See which of 38 healthcare AI stocks may still merit a closer look.
What You Would Have Been Weighing Up With Haemonetics
The shares cost US$80.15 at the start of the period. Anyone looking at Haemonetics then faced two very different but reasonable stories about where value might sit.
The bullish narrative put fair value at US$108, framed around technology-driven recurring revenue and expectations that plasma software and U.S. TEG adoption could support wider margins and higher earnings over several years.
The more cautious view suggested fair value of US$65.5, focused on the idea that reimbursement pressure, regulatory change and competition in Vascular Closure and Interventional Technologies might restrict margin improvement and limit cash flow growth.
What The Evidence Did To The Haemonetics Debate
The expanded CSL Plasma rollout of Haemonetics’ NexSys PCS with Persona PLUS pointed squarely at the bullish story about recurring plasma hardware and disposables. Q1 2027 revenue reached US$339.4 million versus US$321.4 million in Q1 2026, although net income slipped to US$33.0 million and net margin edged down to 9.7%. Overall, the evidence cut both ways.
The practical takeaway is simple. When a thesis hinges on recurring technology usage like Haemonetics’ plasma and software footprint, track contract scope, device deployment plans and segment margins in filings, rather than focusing only on headline growth or upgrades.
What Haemonetics' Run Up 59% Now Asks You To Believe
Haemonetics now trades at US$127, with this Narrative’s Fair Value sitting below that quote rather than above it. The gap rests on the idea that cost inflation, plasma contract terms and hemostasis reinvestment could absorb more of the economic benefit than the share price implies.
A buyer today is effectively assuming that recent revenue trends, margin gains and free cash flow quality can be sustained. The question is how that stacks up against the Narrative’s focus on cost pressure and contract risk around plasma, hemostasis and interventional devices.
"The numbers imply the share price already embeds a continuation of recent revenue growth, margin expansion and cash generation, leaving limited room for disappointment if cost pressures or competitive responses intensify."
One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all
Go Straight To The Source
The story behind this run has already been told. The next one could be taking shape somewhere else. Where could you start looking before it becomes the headline?
- Company 1 - 30% below our estimate - sells certified low-emission engines into larger data center power system orders.
- Company 2 - 45% below our estimate - builds an aviation aftermarket platform scaling higher margin engine and component support contracts.
- Company 3 - 38% below our estimate - advances late stage therapies expanding beyond cystic fibrosis into serious chronic conditions.
Three companies from the same screener. Open all 35 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com